(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 127.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Beone Medicines's revenue in 2025 is $4,562,002,000.On average, 10 Wall Street analysts forecast ONC's revenue for 2025 to be $53,840,669,603,667, with the lowest ONC revenue forecast at $51,473,402,310,182, and the highest ONC revenue forecast at $57,064,730,316,365. On average, 10 Wall Street analysts forecast ONC's revenue for 2026 to be $65,930,182,089,791, with the lowest ONC revenue forecast at $62,268,427,243,071, and the highest ONC revenue forecast at $71,326,979,369,742.
In 2027, ONC is forecast to generate $76,613,637,929,694 in revenue, with the lowest revenue forecast at $69,062,698,931,321 and the highest revenue forecast at $84,103,070,889,626.